Viral Vector API Characterization of Product-Related Impurities

Wunderli,Peter ;Lu,Jun;Ding,Jie;Ames,Mercedes;Wolman,Marc;Finger,Jared;Gacheru,Stephen;

Viral Vector API Characterization of Product-Related Impurities

Published on: October 15, 2020

Peter Wunderli, Jun Lu, Jie Ding, Mercedes Ames, Marc Wolman, Jared Finger, Stephen Gacheru

Pharmaceutical Technology, Pharmaceutical Technology-10-15-2020, Volume 2020 eBook, Issue 3

Pages: 52-58

FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.

In January 2020, the FDA issued Final Guidance for Industry: Chemistry Manufacturing and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) and other guidance documents for human gene therapies, which set expectations for manufacturing and demonstration of quality (1). These products are applied to deliver genetic material (transgenes) or modified cells that have been designed to alleviate or even eliminate a broad range of diseases that are rooted in the genetics of individuals or populations of patients.

Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 52-58

Citation

When referring to this article, please cite it as P. Wunderli et al., “Viral Vector API Characterization of Product-Related Impurities," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).